ERBB2 and breast cancer: Furthermore, Zou and the team found that trastuzumab targets the resistance-related gene FGFR4, inhibiting ferroptosis through the FGFR4-βcatenin/TCF4-SLC7A11 axis and promoting resistance in HER2-positive breast cancer (106).